- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04477681
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults (SACHA)
June 2, 2023 updated by: Gustave Roussy, Cancer Campus, Grand Paris
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults in Therapeutic Failure or Relapse and Not Eligible for a Clinical Trial: a Project of the SFCE
It involves collecting safety and efficacy data, under the actual conditions of use of medicines in children and adolescents, using a validated tool (Ennov EDC) and relying on the network of Interregional pediatric oncology appeal organizations (OIR) identified by INCa since 2010 and responsible for the organization of Pluridisciplinary Pediatric Interregional (RCPPI) and National Consultative Meetings which discuss each case of relapse in order to define the best therapeutic options.
Study Overview
Detailed Description
The objective is to aim for completeness throughout the national territory.
This is why this project will be carried out in close collaboration with the RIOs and RCPPI and that of the 31 centers of the SFCE which bring together more than 400 doctors pediatric oncologists and hematologists on the French territory
Study Type
Observational
Enrollment (Estimated)
750
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pablo BERLANGA, MD
- Phone Number: +33 (0)1 42 11 42 11
- Email: pablo.berlanga@gustaveroussy.fr
Study Contact Backup
- Name: Lee Aymar NDOUNGA DIAKOU, PhD
- Phone Number: +33 (0)1 42 11 42 11
- Email: Leeaymar.NDOUNGA-DIAKOU@gustaveroussy.fr
Study Locations
-
-
-
Amiens, France
- Recruiting
- CHU Amiens
-
Contact:
- Leslie ANDRY, MD
- Email: Andry.Leslie@chu-amiens.fr
-
Angers, France
- Recruiting
- Chu Angers
-
Contact:
- Emilie DE CARLI, MD
- Email: emdecarli@chu-angers.fr
-
Besançon, France
- Recruiting
- CHU Besançon
-
Contact:
- Sébastien KLEIN, MD
- Email: s1klein@chu-besancon.fr
-
Bordeaux, France
- Recruiting
- CHU Bordeaux
-
Contact:
- stephane DUCASSOU, MD
- Email: stephane.ducassou@chu-bordeaux.fr
-
Caen, France
- Recruiting
- CHU caen
-
Contact:
- Damien BODET, MD
- Email: bodet-d@chu-caen.fr
-
Clermont-Ferrand, France
- Recruiting
- Chu Clermont-Ferrand
-
Contact:
- Justyna KANOLD
- Email: jkanold@chu-clermontferrand.fr
-
Dijon, France
- Recruiting
- CHU Dijon
-
Contact:
- Claire BRIANDET, MD
- Email: claire.briandet@chu-dijon.fr
-
Grenoble, France
- Recruiting
- CHU Grenoble
-
Contact:
- Dominique PLANTAZ, MD
- Email: Dplantaz@chu-grenoble.fr
-
Lille, France
- Recruiting
- CHU Lille
-
Contact:
- Brigitte NELKEN, MD
- Email: brigitte.nelken@chru-lille.fr
-
Lille, France
- Recruiting
- Centre OSCAR LAMBRET
-
Contact:
- Sandra RAIMBAULT, MD
- Email: s-raimbault@o-lambret.fr
-
Limoges, France
- Recruiting
- CHU Limoges
-
Contact:
- Christophe PIGUET, MD
- Email: Christophe.piguet@chu-limoges.fr
-
Lyon, France
- Recruiting
- Centre Leon Berard
-
Contact:
- Nadège CORRADINI, MD
- Email: Nadege.CORRADINI@ihope.fr
-
Lyon, France
- Recruiting
- CHU LYON
-
Contact:
- Carine HALFON-DOMENECH, MD
- Email: Carine.HALFONDOMENECH@ihope.fr
-
Marseille, France
- Recruiting
- Hopital de La Timone
-
Contact:
- Nicolas ANDRE, MD
- Email: Nicolas.ANDRE@ap-hm.fr
-
Montpellier, France
- Recruiting
- CHU Montpellier
-
Contact:
- Laure SAUMET, MD
- Email: l-saumet@chu-montpellier.fr
-
Nancy, France
- Recruiting
- Chu Nancy
-
Contact:
- Pascal CHASTAGNER, MD
- Email: p.chastagner@chru-nancy.fr
-
Nantes, France
- Recruiting
- CHU Nantes
-
Contact:
- Morgane CLEIREC, MD
- Email: morgane.cleirec@chu-nantes.fr
-
Nice, France
- Recruiting
- CHU Nice
-
Contact:
- Joy BENADIBA, MD
- Email: benadiba.j@chu-nice.fr
-
Paris, France
- Recruiting
- Hôpital Armand Trousseau
-
Contact:
- Arnaud PETIT, MD
- Email: arnaud.petit@aphp.fr
-
Paris, France
- Recruiting
- Institut Curie
-
Contact:
- Isabelle AERTS, MD
- Email: isabelle.aerts@curie.fr
-
Paris, France
- Recruiting
- Hôpital Robert-Debré
-
Contact:
- Marion STRULLU, MD
- Email: marion.strullu@aphp.fr
-
Poitiers, France
- Recruiting
- CHU Poitiers
-
Contact:
- Frederic MILLOT, MD
- Email: f.millot@chu-poitiers.fr
-
Reims, France
- Recruiting
- CHU Reims
-
Contact:
- Claire PUCHART, MD
- Email: cpluchart@chu-reims.fr
-
Rennes, France
- Recruiting
- CHU Rennes
-
Contact:
- Chloé PUISIEUX, MD
- Email: Chloe.PUISEUX@chu-rennes.fr
-
Rouen, France
- Recruiting
- CHU Rouen
-
Contact:
- Pascal SCHNEIDER
- Email: Pascale.Schneider@chu-rouen.fr
-
Saint-Denis, France
- Recruiting
- CHU La Réunion
-
Contact:
- Yves REGUERRE, MD
- Email: Yves.reguerre@chu-reunion.fr
-
Saint-Étienne, France
- Recruiting
- CHU Saint-Etienne
-
Contact:
- Sandrine THOUVENIN, MD
- Email: sandrine.thouvenin@chu-st-etienne.fr
-
Strasbourg, France
- Recruiting
- CHU Strasbourg
-
Contact:
- Natacha ENTZ-WERLE
- Email: Natacha.Entz-Werle@chru-strasbourg.fr
-
Toulouse, France
- Recruiting
- CHU Toulouse
-
Contact:
- Marion Gambart, MD
- Email: gambart.m@chu-toulouse.fr
-
Tours, France
- Recruiting
- Chu Tours
-
Contact:
- Jill SERRE, MD
- Email: J.SERRE@chu-tours.fr
-
-
Val De Marne
-
Villejuif, Val De Marne, France, 94805
- Recruiting
- Gustave Roussy
-
Contact:
- Pablo BERLANGA, MD
- Phone Number: +33 (0)1 42 11 42 11
- Email: pablo.berlanga@gustaveroussy.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 25 years (Child, Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of an ATU or outside AMM, in one of the centers of the SFCE (Société Française Cancer Enfant).
Description
Inclusion Criteria:
- Age ≤ 25 years old at the time of inclusion in the study
- Patient with a pediatric tumor or leukemia in therapeutic failure or relapse without standard therapeutic options. Exceptionally, patients on the first line of treatment without standard therapeutic options may also be included (eg g: inoperable plexiform neurofibroma and MEK inhibitors, childhood fibrosarcoma and NTRK inhibitors).
- Patient not eligible for an early phase clinical trial open to inclusion on French territory or refusal of inclusion
- Patient treated with a new drug discussed at an ICSID as part of an ATU (nominative or cohort) issued by the ANSM or an off-label prescription of a drug of interest already authorized in adults.
- Patients treated in one of the SFCE centers authorized to prescribe chemotherapy
- Patient who did not object to participate after being informed of the study. The patient must be able and willing to cooperate in the study.
Exclusion Criteria:
- Patient included in an early phase clinical trial open to inclusions on French territory.
- Oral refusal to participate by the patient or their legal representatives, in reading the information note specific to the study
- Patient under guardianship or curatorship, deprived of liberty or in the impossibility of expressing opposition to participating in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients in therapeutic failure or relapse
Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of an ATU or outside AMM, in one of the centers of the SFCE (Société Française Cancer Enfant)
|
In particular, the patient's demographic data, medical history, previous and concomitant treatments, data on the treatment of interest (legal framework, ATU / off-label), dosage, start date, etc.), clinical data will be collected.
biological (including molecular profiling of the tumor if available) and radiological follow-up, information on adverse effects.
The data to be filled in is that of the CERFA pharmacovigilance form of the ANSM, but additional fields can be created if necessary.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collect access data
Time Frame: up to 1 year
|
Collect access data of children, adolescents and young adults in therapeutic failures and not eligible for a clinical trial with innovative molecules, whether they are targeted therapies, immunotherapies or chemotherapies
|
up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 9, 2020
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
April 1, 2026
Study Registration Dates
First Submitted
July 15, 2020
First Submitted That Met QC Criteria
July 15, 2020
First Posted (Actual)
July 20, 2020
Study Record Updates
Last Update Posted (Actual)
June 6, 2023
Last Update Submitted That Met QC Criteria
June 2, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 2019-A01317-50
- 2019/2848 (Other Identifier: CSET number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Cancer
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoSilicon Valley Community FoundationUnknownCancer | Pediatric CancerUnited States
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
Alexandria UniversityCompletedPediatric Cancer | Invasive CancerEgypt
-
University of California, San DiegoNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaboratorsNot yet recruiting
-
Immune Oncology Research InstituteRecruitingContinuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With DexamethasonePediatric CancerArmenia
-
Connecticut Children's Medical CenterThe Hospital for Sick ChildrenRecruitingPediatric CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingPediatric CancerUnited States
-
Erin RowellRecruiting
-
Giselle ShollerRecruiting
Clinical Trials on Data collection
-
Care Management PlusCompletedHealth Information Technology | Nurse Based Care ManagementUnited States
-
University Hospital, Basel, SwitzerlandRecruitingInfections With CPBSwitzerland
-
M.D. Anderson Cancer CenterUnknownPediatric CancerUnited States
-
GlaxoSmithKlineCompletedInfections, StreptococcalRomania, Slovenia, Poland, Lithuania, Estonia
-
GCS Ramsay Santé pour l'Enseignement et la RechercheNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Women and Infants Hospital of Rhode IslandTerminated
-
Centre Hospitalier Universitaire DijonCompletedCoronary Artery Bypass Graft | Anomalies in Glucose MetabolismFrance